Table 3.
Final diagnosis in kidney allograft biopsies from patients with COVID-19 (n = 44), compared to HIV-positive patients (n = 6), from 5 years of total biopsies prior to the COVID-19 pandemic (January 1, 2015 to January 1, 2020; n = 13,955)
| Final diagnosis | COVID (n = 44) |
HIV (n = 6) |
Biopsy database (n = 13,955) |
|||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | P value | n | % | P value | |
| Allograft rejection | 27 | 61.4 | 5 | 83.3 | 0.39 | 3788 | 27.1 | <0.001 |
| Antibody-mediated rejection | 17 | 38.6 | 3 | 50 | ||||
| Acute T cell–mediated rejection | 6 | 13.6 | 2 | 33.3 | ||||
| Antibody + T cell–mediated rejection | 4 | 9.1 | 0 | |||||
| Acute tubular injury | 12 | 27.3 | 1 | 16.7 | 1.0 | 2472 | 17.7 | 0.09 |
| Negative for rejection | 2 | 4.5 | 0 | 0 | 1.0 | 5315 | 38.1 | <0.001 |
| Collapsing glomerulopathy | 2 | 4.5 | 0 | 0 | 1.0 | 187 | 1.3 | 0.12 |
| IgA nephropathy | 1 | 2.3 | 0 | 0 | 1.0 | 371 | 2.7 | 1.0 |
COVID, coronavirus; COVID-19, coronavirus disease 2019.
P values represent comparisons to the COVID-19 patient cohort.